These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 7001229)

  • 41. Normalization of glycemia in diabetics during meals with insulin and glucagon delivery by the artificial pancreas.
    Marliss EB; Murray FT; Stokes EF; Zinman B; Nakhooda AF; Denoga A; Leibel BS; Albisser AM
    Diabetes; 1977 Jul; 26(7):663-72. PubMed ID: 873073
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of a portable insulin infusion pump for outpatient management of brittle diabetes.
    Kitabchi AE; Fisher JN; Burghen GA; Gaylord MS; Blank NM
    Diabetes Care; 1979; 2(5):421-4. PubMed ID: 510142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quality control of intensified insulin therapy: HbA1 versus blood glucose.
    Bischof F; Meyerhoff C; Pfeiffer EF
    Horm Metab Res; 1994 Dec; 26(12):574-8. PubMed ID: 7705761
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic response of normal man and insulin-infused diabetics to postprandial exercise.
    Nelson JD; Poussier P; Marliss EB; Albisser AM; Zinman B
    Am J Physiol; 1982 May; 242(5):E309-16. PubMed ID: 7044140
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term continuous intraperitoneal insulin treatment in brittle diabetes.
    Pozza G; Spotti D; Micossi P; Cristallo M; Melandri M; Piatti PM; Monti LD; Pontiroli AE
    Br Med J (Clin Res Ed); 1983 Jan; 286(6361):255-6. PubMed ID: 6402060
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Five-day programmed intraperitoneal insulin delivery in insulin-dependent diabetic man.
    Schade DS; Eaton RP; Friedman NM; Spencer WJ; Standefer JC
    J Clin Endocrinol Metab; 1981 Jun; 52(6):1165-70. PubMed ID: 7014596
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Roles of site and timing of the morning insulin injection in type 1 diabetes.
    Witt MF; White NH; Santiago JV
    J Pediatr; 1983 Oct; 103(4):528-33. PubMed ID: 6352884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of continuous subcutaneous insulin infusion.
    Lauritzen T; Pramming S; Deckert T; Binder C
    Diabetologia; 1983 May; 24(5):326-9. PubMed ID: 6347780
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of insulin-dependent diabetes by continuous subcutaneous infusion of insulin (author's transl)].
    Buysschaert M; Lejeune M; Lambert AE
    Ann Endocrinol (Paris); 1981; 42(3):293-4. PubMed ID: 7316465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of platelet thromboxane synthesis in diabetic patients on conventional insulin therapy and continuous insulin infusions.
    McDonald JW; Dupre J; Rodger NW; Champion MC; Webb CD; Ali M
    Thromb Res; 1982 Dec; 28(6):705-12. PubMed ID: 6762683
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus.
    Dimitriadis GD; Gerich JE
    Diabetes Care; 1983; 6(4):374-7. PubMed ID: 6352210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A simple and rational twice daily insulin regime. Distinction between basal and meal insulin requirements.
    Phillips M; Simpson RW; Holman RR; Turner RC
    Q J Med; 1979 Jul; 48(191):493-506. PubMed ID: 396545
    [No Abstract]   [Full Text] [Related]  

  • 53. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion.
    Pezzarossa A; Taddei F; Cimicchi MC; Rossini E; Contini S; Bonora E; Gnudi A; Uggeri E
    Diabetes Care; 1988 Jan; 11(1):52-8. PubMed ID: 3276477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reproducibility of insulin dosage on consecutive days of blood glucose control by an artificial beta-cell in brittle diabetic patients.
    Bruns W; Bombor H; Jutzi E; Ratzmann KP; Schulz B; Abel P; Fischer U
    Diabetes Care; 1983; 6(2):112-7. PubMed ID: 6343014
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical application and significance of drug delivery systems. Insulin injection therapy of diabetes].
    Iwaoka H; Tsuchida H; Makino H; Yoshida S
    Nihon Rinsho; 1989 Jun; 47(6):1329-34. PubMed ID: 2671444
    [No Abstract]   [Full Text] [Related]  

  • 56. Plasma insulin and C-peptide levels during continuous subcutaneous insulin infusion.
    Slama G; Buu KN; Tchobroutsky G; Delage A; Desplanque N
    Diabetes Care; 1979; 2(3):251-5. PubMed ID: 510116
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determination of insulin requirements in brittle diabetic patients by the artificial pancreas.
    Lambert AE; Buysschaert M; Marchand E; Pierard M; Wojcik S; Lambotte L
    Diabetes; 1978 Aug; 27(8):825-33. PubMed ID: 680409
    [No Abstract]   [Full Text] [Related]  

  • 58. Hyperinsulinism complicating control of diabetes mellitus by an artificial beta-cell.
    Horwitz DL; Zeidler A; Gonen B; Jaspan JB
    Diabetes Care; 1980; 3(2):274-7. PubMed ID: 6993140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improved control in diabetes with continuous subcutaneous insulin infusion.
    Schiffrin A; Colle E; Belmonte M
    Diabetes Care; 1980; 3(6):643-9. PubMed ID: 7004811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison between the plasma insulin and glucose responses to five different insulin regimes in diabetic patients.
    Gokal R; Harding P; Turner RC
    Clin Endocrinol (Oxf); 1977 Oct; 7(4):301-5. PubMed ID: 923108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.